Means and methods for detoxifying ochratoxin a

A foodstuff, intermediate foodstuff;

• fodder, intermediate fodder;
• feed, intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff, fodder- or feed intermediate additive);
• detoxifying agent, intermediate detoxifying agent;
• nutritional supplement, intermediate nutritional supplement;
• prebiotic, intermediate prebiotic and/or mixture/s thereof, comprising one or more of the following:
• (i) one or more polypeptides having at least 70% sequence identity (e.g. at least 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) to the amino acid sequence selected from the group consisting of:
• SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 22, SEQ ID NO:
• 318, SEQ ID NO:
• 336, SEQ ID NO:
• 348, SEQ ID NOs:
• 16-359, 368-370;
• wherein said polypeptide/s are capable of detoxifying (e.g., modifying or hydrolyzing) at least one mycotoxin having said Formula I (e.g., Ochratoxin A, Ochratoxin B and/or Ochratoxin C):
• wherein R1 is selected from the group consisting of H and OH, R2 is selected from the group consisting of H and CH2—CH3 and R3 is selected from the group consisting of H and Cl;
• preferably said polypeptide/s having a peptidase activity having EC 3.4.13.X, wherein X is selected from the group consisting of:
• 9, 4, 5, 7, 12, 17, 18, 19, 20, 21, 22, 23;
• further preferably said polypeptide/s having a peptidase activity having EC 3.4.13.9;
• most preferably said polypeptide/s comprising one or more of the following amino acid sequences (e.g., conservative motifs):
• i′) PGFIDAHVH (SEQ ID NO:
• 3), preferably said SEQ ID NO:
• 3 is comprised at amino acid positions corresponding to positions 87-95 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• ii′) PAEQA (SEQ ID NO:
• 4), preferably said SEQ ID NO:
• 4 is comprised at amino acid positions corresponding to positions 116-120 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• iii′) GVCNG (SEQ ID NO:
• 5), preferably said SEQ ID NO:
• 5 is comprised at amino acid positions corresponding to positions 197-201 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• iv′) CRAAVR (SEQ ID NO:
• 6), preferably said SEQ ID NO:
• 6 is comprised at amino acid positions corresponding to positions 205-210 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• v′) IKFMPSGGVLSL (SEQ ID NO:
• 7), preferably said SEQ ID NO:
• 7 is comprised at amino acid positions corresponding to positions 220-231 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• vi′) RKVAAH (SEQ ID NO:
• 8), preferably said SEQ ID NO:
• 8 is comprised at amino acid positions corresponding to positions 257-262 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• vii′) AGVDSIEHG (SEQ ID NO:
• 9), preferably said SEQ ID NO:
• 9 is comprised at amino acid positions corresponding to positions 275-283 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• viii′) VMPGLIDAH (SEQ ID NO:
• 10), preferably said SEQ ID NO:
• 10 is comprised at amino acid positions corresponding to positions 51-59 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• ix′) AGFTTVRDCG (SEQ ID NO:
• 11), preferably said SEQ ID NO:
• 11 is comprised at amino acid positions corresponding to positions 96-105 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• x′) QTFGH (SEQ ID NO:
• 12), preferably said SEQ ID NO:
• 12 is comprised at amino acid positions corresponding to positions 135-139 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xi′) ATGGVLS (SEQ ID NO:
• 13), preferably said SEQ ID NO:
• 13 is comprised at amino acid positions corresponding to positions 185-191 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xii′) YVAAHAHGD (SEQ ID NO:
• 14), preferably said SEQ ID NO:
• 14 is comprised at amino acid positions corresponding to positions 219-227 of SEQ ID NO:
• 2 or 22 (e.g., using the numbering of SEQ ID NO:
• 2 or 22);
• xiii′) LTPTL (SEQ ID NO:
• 15), preferably said SEQ ID NO:
• 15 is comprised at amino acid positions corresponding to positions 262-266 of SEQ ID NO:
• 2 or 22 (e.g., using the numbering of SEQ ID NO:
• 2 or 22);
• xiv′) VMPGLID (SEQ ID NO:
• 360), preferably said SEQ ID NO:
• 360 is comprised at amino acid positions corresponding to positions 52-58 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xv′) KGGSL (SEQ ID NO:
• 361), preferably said SEQ ID NO:
• 361 is comprised at amino acid positions corresponding to positions 67-71 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xvi′) LLLAGFTTVRDCG (SEQ ID NO:
• 362), preferably said SEQ ID NO:
• 362 is comprised at amino acid positions corresponding to positions 93-105 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xvii′) QTFGHGE (SEQ ID NO:
• 363), preferably said SEQ ID NO:
• 363 is comprised at amino acid positions corresponding to positions 135-141 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xviii′) FATGGVLSQRD (SEQ ID NO:
• 364), preferably said SEQ ID NO:
• 364 is comprised at amino acid positions corresponding to positions 184-194 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xix′) IVNEA (SEQ ID NO:
• 365), preferably said SEQ ID NO:
• 365 is comprised at amino acid positions corresponding to positions 209-213 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xx′) IGVDEWGL (SEQ ID NO:
• 366), preferably said SEQ ID NO:
• 366 is comprised at amino acid positions corresponding to positions 279-286 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xxi′) GFETGL (SEQ ID NO:
• 367), preferably said SEQ ID NO:
• 367 is comprised at amino acid positions corresponding to positions 317-322 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22).
• ii) one or more variants of a parent polypeptide, wherein said variant/s comprising an alteration (e.g., a substitution, deletion and/or insertion) at one or more positions corresponding to positions of the parent polypeptide, wherein said variant/s having at least 70% (e.g. at least 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%), but less than 100% sequence identity to a parent amino acid sequence selected from the group consisting of:
• SEQ ID NOs 1, 2, 16-21, 22, 23-34, 317-318, 326-335, 336-337, 348-349, 368-370;
• wherein said variant/s are capable of detoxifying (e.g., modifying or hydrolyzing) at least one mycotoxin having said Formula I (e.g., Ochratoxin A, Ochratoxin B and/or Ochratoxin C);
• preferably said variant/s having a peptidase activity having EC 3.4.13.X, wherein X is selected from the group consisting of:
• 9, 4, 5, 7, 12, 17, 18, 19, 20, 21, 22, 23;
• further preferably said variant/s having a peptidase activity having EC 3.4.13.9;
• most preferably said variant/s comprising one or more of the following amino acid sequences (e.g., conservative motifs):
• (i′)-(xxi′) according to (i);
• (iii) one or more polynucleotides, nucleic acid constructs and/or expression vectors encoding and/or capable of expressing one or more polypeptides and/or one or more variants according to (i)-(ii);
• and/or
• (iv) one or more recombinant host cells, spores, transgenic plants, transgenic seeds and/or transgenic pollen grains comprising (i), (ii) and/or (iii).

A variant of a parent polypeptide capable of detoxifying (e.g., modifying or hydrolyzing) at least one mycotoxin having said Formula I (e.g., Ochratoxin A, Ochratoxin B and/or Ochratoxin C):

• wherein R1 is selected from the group consisting of H and OH, R2 is selected from the group consisting of H and CH2—CH3 and R3 is selected from the group consisting of H and Cl;
• wherein said variant comprising an alteration (e.g., a substitution, deletion and/or insertion) at one or more positions corresponding to positions of the parent polypeptide, wherein said variant/s having at least 70% (e.g. at least 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%), but less than 100% sequence identity to a parent amino acid sequence selected from the group consisting of:
• SEQ ID NOs 1, 2, 16-21, 22, 23-34, 317-318, 326-335, 336-337, 348-349, 368-370;
• preferably said variant having a peptidase activity having EC 3.4.13.X, wherein X is selected from the group consisting of:
• 9, 4, 5, 7, 12, 17, 18, 19, 20, 21, 22, 23;
• further preferably said variant having a peptidase activity having EC 3.4.13.9;
• most preferably, said variant comprising one or more of the following amino acid sequences (e.g., conservative motifs):
• i′) PGFIDAHVH (SEQ ID NO:
• 3), preferably said SEQ ID NO:
• 3 is comprised at amino acid positions corresponding to positions 87-95 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• ii′) PAEQA (SEQ ID NO:
• 4), preferably said SEQ ID NO:
• 4 is comprised at amino acid positions corresponding to positions 116-120 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• iii′) GVCNG (SEQ ID NO:
• 5), preferably said SEQ ID NO:
• 5 is comprised at amino acid positions corresponding to positions 197-201 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• iv′) CRAAVR (SEQ ID NO:
• 6), preferably said SEQ ID NO:
• 6 is comprised at amino acid positions corresponding to positions 205-210 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• v′) IKFMPSGGVLSL (SEQ ID NO:
• 7), preferably said SEQ ID NO:
• 7 is comprised at amino acid positions corresponding to positions 220-231 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• vi′) RKVAAH (SEQ ID NO:
• 8), preferably said SEQ ID NO:
• 8 is comprised at amino acid positions corresponding to positions 257-262 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• vii′) AGVDSIEHG (SEQ ID NO:
• 9), preferably said SEQ ID NO:
• 9 is comprised at amino acid positions corresponding to positions 275-283 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• viii′) VMPGLIDAH (SEQ ID NO:
• 10), preferably said SEQ ID NO:
• 10 is comprised at amino acid positions corresponding to positions 51-59 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• ix′) AGFTTVRDCG (SEQ ID NO:
• 11), preferably said SEQ ID NO:
• 11 is comprised at amino acid positions corresponding to positions 96-105 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• x′) QTFGH (SEQ ID NO:
• 12), preferably said SEQ ID NO:
• 12 is comprised at amino acid positions corresponding to positions 135-139 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xi′) ATGGVLS (SEQ ID NO:
• 13), preferably said SEQ ID NO:
• 13 is comprised at amino acid positions corresponding to positions 185-191 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xii′) YVAAHAHGD (SEQ ID NO:
• 14), preferably said SEQ ID NO:
• 14 is comprised at amino acid positions corresponding to positions 219-227 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xiii′) LTPTL (SEQ ID NO:
• 15), preferably said SEQ ID NO:
• 15 is comprised at amino acid positions corresponding to positions 262-266 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xiv′) VMPGLID (SEQ ID NO:
• 360), preferably said SEQ ID NO:
• 360 is comprised at amino acid positions corresponding to positions 52-58 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xv′) KGGSL (SEQ ID NO:
• 361), preferably said SEQ ID NO:
• 361 is comprised at amino acid positions corresponding to positions 67-71 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xvi′) LLLAGFTTVRDCG (SEQ ID NO:
• 362), preferably said SEQ ID NO:
• 362 is comprised at amino acid positions corresponding to positions 93-105 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xvii′) QTFGHGE (SEQ ID NO:
• 363), preferably said SEQ ID NO:
• 363 is comprised at amino acid positions corresponding to positions 135-141 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xviii′) FATGGVLSQRD (SEQ ID NO:
• 364), preferably said SEQ ID NO:
• 364 is comprised at amino acid positions corresponding to positions 184-194 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xix′) IVNEA (SEQ ID NO:
• 365), preferably said SEQ ID NO:
• 365 is comprised at amino acid positions corresponding to positions 209-213 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xx′) IGVDEWGL (SEQ ID NO:
• 366), preferably said SEQ ID NO:
• 366 is comprised at amino acid positions corresponding to positions 279-286 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xxi′) GFETGL (SEQ ID NO:
• 367), preferably said SEQ ID NO:
• 367 is comprised at amino acid positions corresponding to positions 317-322 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22).

The method, variant, foodstuff, intermediate foodstuff;

• fodder, intermediate fodder;
• feed, intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff, fodder- or feed intermediate additive), detoxifying agent, intermediate detoxifying agent, nutritional supplement, intermediate nutritional supplement;
• prebiotic, intermediate prebiotic and/or mixture/s thereof according to any one of the preceding claims, wherein said polypeptide and/or variant having one or more of the following:
• i) said peptidase activity is a Xaa-Pro dipeptidase EC 3.4.13.9;
• ii) said polypeptide and/or variant having a TIM barrel structure comprising 8 α-helices and 8 parallel β-strands alternating along the polypeptide backbone, wherein preferably said TIM barrel further comprising a phosphate binding site;
• iii) said polypeptide and/or variant having a specific activity of at least 2.9 U/g at pH7.5;
• iv) said polypeptide and/or variant having a specific activity of at least 0.9 U/g at pH6.0;
• v) said polypeptide and/or variant having a T50 value of more than 80° C. (e.g. more than 85° C.);
• vi) said polypeptide is selected from the group consisting of:
• SEQ ID NOs 1, 2, 16-21, 22, 23-34, 317-318, 326-335, 336-337, 348-349, 368-370;
• and/or
• vii) said variant is selected from the group consisting of:
• SEQ ID NOs:
• 35-316, 319-325, 338-347, 350-359.

The method, variant, foodstuff, intermediate foodstuff;

• fodder, intermediate fodder;
• feed, intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff, fodder- or feed intermediate additive);
• detoxifying agent, intermediate detoxifying agent;
• nutritional supplement, intermediate nutritional supplement;
• prebiotic, intermediate prebiotic and/or mixture/s thereof according to any one of the preceding claims, wherein said variant comprising an alteration (e.g., a substitution, deletion and/or insertion) at one or more positions corresponding to positions 65,106,132, 268, 269, 272, 275 and/or 318 of SEQ ID NO:
• 2, preferably using the numbering of SEQ ID NO:
• 2.

The method, variant, foodstuff, intermediate foodstuff;

• fodder, intermediate fodder;
• feed, intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff, fodder- or feed intermediate additive);
• detoxifying agent, intermediate detoxifying agent;
• nutritional supplement, intermediate nutritional supplement;
• prebiotic, intermediate prebiotic and/or mixture/s thereof according to any one of the preceding claims, wherein said variant comprising an alteration (e.g., a substitution, deletion and/or insertion) at one or more positions corresponding to positions 30, 36, 50, 85, 97, 98, 99, 100, 103, 104, 105, 106, 107, 108, 109, 111, 112, 113, 119, 122, 126, 130, 142, 143, 144, 170, 171, 176, 178, 179, 181, 183, 184, 187, 188, 192, 198, 223, 226, 228, 229, 230, 231, 233, 235, 239, 242, 253, 264, 284, 287, 307, 308, 310, 311, 314, 315, 317, 318, 322, 329, 330, 332, 333, 339, 353, 354, 355, 356, 357, 358 or 361 of SEQ ID NOs:
• 1 or 318, preferably using the numbering of SEQ ID NO:
• 1 or 318, further preferably using the numbering of SEQ ID NO:
• 318.

A composition or kit comprising one or more of the following:

• variants, nucleic acid constructs, expression vectors, recombinant host cells, spores, transgenic plants, transgenic seeds and/or transgenic pollen grains, foodstuff, intermediate foodstuff;
• fodder, intermediate fodder;
• feed, intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff-, fodder- or feed intermediate additive);
• detoxifying agent, intermediate detoxifying agent;
• nutritional supplement, intermediate nutritional supplement, prebiotic, intermediate prebiotic and/or mixture/s thereof according to any one of the preceding claims and/or one or more polypeptides having at least 70% sequence identity (e.g. at least 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) to the amino acid sequence selected from the group consisting of:
• SEQ ID NOs:
• 1, 2, 16-21, 22, 23-34, 317-318, 326-335, 336-337, 348-349, 368-370, 35-316, 319-325, 338-347, 350-359;
• wherein said polypeptide/s are capable of detoxifying (e.g., modifying or hydrolyzing) at least one mycotoxin having said Formula I:
• wherein R1 is selected from the group consisting of H and OH, R2 is selected from the group consisting of H and CH2—CH3 and R3 is selected from the group consisting of H and Cl;
• preferably said polypeptide/s having a peptidase activity having EC 3.4.13.X, wherein X is selected from the group consisting of:
• 9, 4, 5, 7, 12, 17, 18, 19, 20, 21, 22, 23;
• further preferably said polypeptide/s having a peptidase activity having EC 3.4.13.9;
• most preferably said polypeptide/s comprising one or more of the following amino acid sequences (e.g., conservative motifs):
• i′) PGFIDAHVH (SEQ ID NO:
• 3), preferably said SEQ ID NO:
• 3 is comprised at amino acid positions corresponding to positions 87-95 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• ii′) PAEQA (SEQ ID NO:
• 4), preferably said SEQ ID NO:
• 4 is comprised at amino acid positions corresponding to positions 116-120 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• iii′) GVCNG (SEQ ID NO:
• 5), preferably said SEQ ID NO:
• 5 is comprised at amino acid positions corresponding to positions 197-201 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• iv′) CRAAVR (SEQ ID NO:
• 6), preferably said SEQ ID NO:
• 6 is comprised at amino acid positions corresponding to positions 205-210 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• v′) IKFMPSGGVLSL (SEQ ID NO:
• 7), preferably said SEQ ID NO:
• 7 is comprised at amino acid positions corresponding to positions 220-231 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• vi′) RKVAAH (SEQ ID NO:
• 8), preferably said SEQ ID NO:
• 8 is comprised at amino acid positions corresponding to positions 257-262 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• vii′) AGVDSIEHG (SEQ ID NO:
• 9), preferably said SEQ ID NO:
• 9 is comprised at amino acid positions corresponding to positions 275-283 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• viii′) VMPGLIDAH (SEQ ID NO:
• 10), preferably said SEQ ID NO:
• 10 is comprised at amino acid positions corresponding to positions 51-59 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• ix′) AGFTTVRDCG (SEQ ID NO:
• 11), preferably said SEQ ID NO:
• 11 is comprised at amino acid positions corresponding to positions 96-105 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• x′) QTFGH (SEQ ID NO:
• 12), preferably said SEQ ID NO:
• 12 is comprised at amino acid positions corresponding to positions 135-139 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xi′) ATGGVLS (SEQ ID NO:
• 13), preferably said SEQ ID NO:
• 13 is comprised at amino acid positions corresponding to positions 185-191 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xii′) YVAAHAHGD (SEQ ID NO:
• 14), preferably said SEQ ID NO:
• 14 is comprised at amino acid positions corresponding to positions 219-227 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xiii′) LTPTL (SEQ ID NO:
• 15), preferably said SEQ ID NO:
• 15 is comprised at amino acid positions corresponding to positions 262-266 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xiv′) VMPGLID (SEQ ID NO:
• 360), preferably said SEQ ID NO:
• 360 is comprised at amino acid positions corresponding to positions 52-58 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xv′) KGGSL (SEQ ID NO:
• 361), preferably said SEQ ID NO:
• 361 is comprised at amino acid positions corresponding to positions 67-71 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xvi′) LLLAGFTTVRDCG (SEQ ID NO:
• 362), preferably said SEQ ID NO:
• 362 is comprised at amino acid positions corresponding to positions 93-105 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xvii′) QTFGHGE (SEQ ID NO:
• 363), preferably said SEQ ID NO:
• 363 is comprised at amino acid positions corresponding to positions 135-141 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xviii′) FATGGVLSQRD (SEQ ID NO:
• 364), preferably said SEQ ID NO:
• 364 is comprised at amino acid positions corresponding to positions 184-194 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xix′) IVNEA (SEQ ID NO:
• 365), preferably said SEQ ID NO:
• 365 is comprised at amino acid positions corresponding to positions 209-213 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xx′) IGVDEWGL (SEQ ID NO:
• 366), preferably said SEQ ID NO:
• 366 is comprised at amino acid positions corresponding to positions 279-286 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xxi′) GFETGL (SEQ ID NO:
• 367), preferably said SEQ ID NO:
• 367 is comprised at amino acid positions corresponding to positions 317-322 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22).

A method for producing a foodstuff, intermediate foodstuff;

• fodder, intermediate fodder;
• feed, intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff, fodder- or feed intermediate additive);
• detoxifying agent, intermediate detoxifying agent;
• nutritional supplement, intermediate nutritional supplement;
• prebiotic, intermediate prebiotic and/or mixture/s thereof, said method comprising:
• a) providing:
• (i) one or more polypeptides having at least 70% sequence identity (e.g. at least 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) to the amino acid sequence selected from the group consisting of:
• SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 22, SEQ ID NO:
• 318, SEQ ID NO:
• 336, SEQ ID NO:
• 348, SEQ ID NOs:
• 16-359, 368-370;
• wherein said polypeptide/s are capable of detoxifying (e.g., modifying or hydrolyzing) at least one mycotoxin having said Formula I (e.g., Ochratoxin A, Ochratoxin B and/or Ochratoxin C):
• wherein R1 is selected from the group consisting of H and OH, R2 is selected from the group consisting of H and CH2—CH3 and R3 is selected from the group consisting of H and Cl;
• preferably said polypeptide/s having a peptidase activity having EC 3.4.13.X, wherein X is selected from the group consisting of:
• 9, 4, 5, 7, 12, 17, 18, 19, 20, 21, 22, 23;
• further preferably said polypeptide/s having a peptidase activity having EC 3.4.13.9;
• most preferably said polypeptide/s comprising one or more of the following amino acid sequences (e.g., conservative motifs):
• i′) PGFIDAHVH (SEQ ID NO:
• 3), preferably said SEQ ID NO:
• 3 is comprised at amino acid positions corresponding to positions 87-95 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• ii′) PAEQA (SEQ ID NO:
• 4), preferably said SEQ ID NO:
• 4 is comprised at amino acid positions corresponding to positions 116-120 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• iii′) GVCNG (SEQ ID NO:
• 5), preferably said SEQ ID NO:
• 5 is comprised at amino acid positions corresponding to positions 197-201 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• iv′) CRAAVR (SEQ ID NO:
• 6), preferably said SEQ ID NO:
• 6 is comprised at amino acid positions corresponding to positions 205-210 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• v′) IKFMPSGGVLSL (SEQ ID NO:
• 7), preferably said SEQ ID NO:
• 7 is comprised at amino acid positions corresponding to positions 220-231 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• vi′) RKVAAH (SEQ ID NO:
• 8), preferably said SEQ ID NO:
• 8 is comprised at amino acid positions corresponding to positions 257-262 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• vii′) AGVDSIEHG (SEQ ID NO:
• 9), preferably said SEQ ID NO:
• 9 is comprised at amino acid positions corresponding to positions 275-283 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• viii′) VMPGLIDAH (SEQ ID NO:
• 10), preferably said SEQ ID NO:
• 10 is comprised at amino acid positions corresponding to positions 51-59 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• ix′) AGFTTVRDCG (SEQ ID NO:
• 11), preferably said SEQ ID NO:
• 11 is comprised at amino acid positions corresponding to positions 96-105 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• x′) QTFGH (SEQ ID NO:
• 12), preferably said SEQ ID NO:
• 12 is comprised at amino acid positions corresponding to positions 135-139 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xi′) ATGGVLS (SEQ ID NO:
• 13), preferably said SEQ ID NO:
• 13 is comprised at amino acid positions corresponding to positions 185-191 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xii′) YVAAHAHGD (SEQ ID NO:
• 14), preferably said SEQ ID NO:
• 14 is comprised at amino acid positions corresponding to positions 219-227 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xiii′) LTPTL (SEQ ID NO:
• 15), preferably said SEQ ID NO:
• 15 is comprised at amino acid positions corresponding to positions 262-266 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xiv′) VMPGLID (SEQ ID NO:
• 360), preferably said SEQ ID NO:
• 360 is comprised at amino acid positions corresponding to positions 52-58 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xv′) KGGSL (SEQ ID NO:
• 361), preferably said SEQ ID NO:
• 361 is comprised at amino acid positions corresponding to positions 67-71 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xvi′) LLLAGFTTVRDCG (SEQ ID NO:
• 362), preferably said SEQ ID NO:
• 362 is comprised at amino acid positions corresponding to positions 93-105 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xvii′) QTFGHGE (SEQ ID NO:
• 363), preferably said SEQ ID NO:
• 363 is comprised at amino acid positions corresponding to positions 135-141 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xviii′) FATGGVLSQRD (SEQ ID NO:
• 364), preferably said SEQ ID NO:
• 364 is comprised at amino acid positions corresponding to positions 184-194 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xix′) IVNEA (SEQ ID NO:
• 365), preferably said SEQ ID NO:
• 365 is comprised at amino acid positions corresponding to positions 209-213 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xx′) IGVDEWGL (SEQ ID NO:
• 366), preferably said SEQ ID NO:
• 366 is comprised at amino acid positions corresponding to positions 279-286 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xxi′) GFETGL (SEQ ID NO:
• 367), preferably said SEQ ID NO:
• 367 is comprised at amino acid positions corresponding to positions 317-322 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22),
• (ii) variants according to any one of the preceding claims;
• (iii) one or more polynucleotides according to any one of the preceding claims;
• (iv) one or more nucleic acid constructs and/or expression vectors according to any one of the preceding claims;
• and/or
• (v) one or more recombinant host cells, spores, transgenic plants, transgenic seeds and/or transgenic pollen grains according to any one of the preceding claims;
• preferably said one or more polypeptides are one or more recombinant and/or isolated polypeptides;
• b) applying (a) to a nutritive source or material suitable for production of foodstuff, intermediate foodstuff;
• fodder, intermediate fodder;
• feed, intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff, fodder- or feed intermediate additive);
• detoxifying agent, intermediate detoxifying agent;
• nutritional supplement, intermediate nutritional supplement;
• prebiotic, intermediate prebiotic and/or mixture/s thereof.

A foodstuff, intermediate foodstuff;

• fodder, intermediate fodder;
• feed, intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff, fodder- or feed intermediate additive);
• detoxifying agent, intermediate detoxifying agent;
• nutritional supplement, intermediate nutritional supplement;
• prebiotic, intermediate prebiotic and/or mixture/s thereof produced by the method according to any one of the preceding claims.

The variant, polynucleotide, nucleic acid construct, expression vector, recombinant host cell, spore, transgenic plant, transgenic seed, transgenic pollen grain, foodstuff, intermediate foodstuff;

• fodder, intermediate fodder;
• feed, intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff, fodder- or feed intermediate additive);
• detoxifying agent, intermediate detoxifying agent;
• nutritional supplement, intermediate nutritional supplement;
• prebiotic, intermediate prebiotic or mixture/s thereof, composition or kit according to any one of the preceding claims and/or one or more polypeptides having at least 70% sequence identity (e.g. at least 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) to the amino acid sequence selected from the group consisting of:
• SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 22, SEQ ID NO:
• 318, SEQ ID NO:
• 336, SEQ ID NO:
• 348, SEQ ID NOs:
• 16-359, 368-370;
• wherein said polypeptide/s are capable of detoxifying (e.g., modifying or hydrolyzing) at least one mycotoxin having said Formula I (e.g., Ochratoxin A, Ochratoxin B and/or Ochratoxin C):
• wherein R1 is selected from the group consisting of H and OH, R2 is selected from the group consisting of H and CH2—CH3 and R3 is selected from the group consisting of H and Cl;
• preferably said polypeptide/s having a peptidase activity having EC 3.4.13.X, wherein X is selected from the group consisting of:
• 9, 4, 5, 7, 12, 17, 18, 19, 20, 21, 22, 23;
• further preferably said polypeptide/s having a peptidase activity having EC 3.4.13.9;
• most preferably said polypeptide/s comprising one or more of the following amino acid sequences (e.g., conservative motifs):
• i′) PGFIDAHVH (SEQ ID NO:
• 3), preferably said SEQ ID NO:
• 3 is comprised at amino acid positions corresponding to positions 87-95 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• ii′) PAEQA (SEQ ID NO:
• 4), preferably said SEQ ID NO:
• 4 is comprised at amino acid positions corresponding to positions 116-120 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• iii′) GVCNG (SEQ ID NO:
• 5), preferably said SEQ ID NO:
• 5 is comprised at amino acid positions corresponding to positions 197-201 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• iv′) CRAAVR (SEQ ID NO:
• 6), preferably said SEQ ID NO:
• 6 is comprised at amino acid positions corresponding to positions 205-210 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• v′) IKFMPSGGVLSL (SEQ ID NO:
• 7), preferably said SEQ ID NO:
• 7 is comprised at amino acid positions corresponding to positions 220-231 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• vi′) RKVAAH (SEQ ID NO:
• 8), preferably said SEQ ID NO:
• 8 is comprised at amino acid positions corresponding to positions 257-262 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• vii′) AGVDSIEHG (SEQ ID NO:
• 9), preferably said SEQ ID NO:
• 9 is comprised at amino acid positions corresponding to positions 275-283 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• viii′) VMPGLIDAH (SEQ ID NO:
• 10), preferably said SEQ ID NO:
• 10 is comprised at amino acid positions corresponding to positions 51-59 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• ix′) AGFTTVRDCG (SEQ ID NO:
• 11), preferably said SEQ ID NO:
• 11 is comprised at amino acid positions corresponding to positions 96-105 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• x′) QTFGH (SEQ ID NO:
• 12), preferably said SEQ ID NO:
• 12 is comprised at amino acid positions corresponding to positions 135-139 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xi′) ATGGVLS (SEQ ID NO:
• 13), preferably said SEQ ID NO:
• 13 is comprised at amino acid positions corresponding to positions 185-191 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xii′) YVAAHAHGD (SEQ ID NO:
• 14), preferably said SEQ ID NO:
• 14 is comprised at amino acid positions corresponding to positions 219-227 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xiii′) LTPTL (SEQ ID NO:
• 15), preferably said SEQ ID NO:
• 15 is comprised at amino acid positions corresponding to positions 262-266 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xiv′) VMPGLID (SEQ ID NO:
• 360), preferably said SEQ ID NO:
• 360 is comprised at amino acid positions corresponding to positions 52-58 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xv′) KGGSL (SEQ ID NO:
• 361), preferably said SEQ ID NO:
• 361 is comprised at amino acid positions corresponding to positions 67-71 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xvi′) LLLAGFTTVRDCG (SEQ ID NO:
• 362), preferably said SEQ ID NO:
• 362 is comprised at amino acid positions corresponding to positions 93-105 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xvii′) QTFGHGE (SEQ ID NO:
• 363), preferably said SEQ ID NO:
• 363 is comprised at amino acid positions corresponding to positions 135-141 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xviii′) FATGGVLSQRD (SEQ ID NO:
• 364), preferably said SEQ ID NO:
• 364 is comprised at amino acid positions corresponding to positions 184-194 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xix′) IVNEA (SEQ ID NO:
• 365), preferably said SEQ ID NO:
• 365 is comprised at amino acid positions corresponding to positions 209-213 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xx′) IGVDEWGL (SEQ ID NO:
• 366), preferably said SEQ ID NO:
• 366 is comprised at amino acid positions corresponding to positions 279-286 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xxi′) GFETGL (SEQ ID NO:
• 367), preferably said SEQ ID NO:
• 367 is comprised at amino acid positions corresponding to positions 317-322 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22),
• for use as a medicament (e.g., for veterinary use) and/or in therapy and/or prophylaxis of a disease.

The variant, polynucleotide, nucleic acid construct, expression vector, recombinant host cell, spore, transgenic plant, transgenic seed, transgenic pollen grain, foodstuff, intermediate foodstuff;

• fodder, intermediate fodder;
• feed, intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff, fodder- or feed intermediate additive);
• detoxifying agent, intermediate detoxifying agent;
• nutritional supplement, intermediate nutritional supplement;
• prebiotic, intermediate prebiotic or mixture/s thereof, composition or kit according to any one of the preceding claims and/or one or more polypeptides having at least 70% sequence identity (e.g. at least 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) to the amino acid sequence selected from the group consisting of:
• SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 22, SEQ ID NO:
• 318, SEQ ID NO:
• 336, SEQ ID NO:
• 348, SEQ ID NOs:
• 16-359, 368-370;
• wherein said polypeptide/s are capable of detoxifying (e.g., modifying or hydrolyzing) at least one mycotoxin having said Formula I (e.g., Ochratoxin A, Ochratoxin B and/or Ochratoxin C):
• wherein R1 is selected from the group consisting of H and OH, R2 is selected from the group consisting of H and CH2—CH3 and R3 is selected from the group consisting of H and Cl;
• preferably said polypeptide/s having a peptidase activity having EC 3.4.13.X, wherein X is selected from the group consisting of:
• 9, 4, 5, 7, 12, 17, 18, 19, 20, 21, 22, 23;
• further preferably said polypeptide/s having a peptidase activity having EC 3.4.13.9;
• most preferably said polypeptide/s comprising one or more of the following amino acid sequences (e.g., conservative motifs):
• i′) PGFIDAHVH (SEQ ID NO:
• 3), preferably said SEQ ID NO:
• 3 is comprised at amino acid positions corresponding to positions 87-95 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• ii′) PAEQA (SEQ ID NO:
• 4), preferably said SEQ ID NO:
• 4 is comprised at amino acid positions corresponding to positions 116-120 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• iii′) GVCNG (SEQ ID NO:
• 5), preferably said SEQ ID NO:
• 5 is comprised at amino acid positions corresponding to positions 197-201 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• iv′) CRAAVR (SEQ ID NO:
• 6), preferably said SEQ ID NO:
• 6 is comprised at amino acid positions corresponding to positions 205-210 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• v′) IKFMPSGGVLSL (SEQ ID NO:
• 7), preferably said SEQ ID NO:
• 7 is comprised at amino acid positions corresponding to positions 220-231 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• vi′) RKVAAH (SEQ ID NO:
• 8), preferably said SEQ ID NO:
• 8 is comprised at amino acid positions corresponding to positions 257-262 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• vii′) AGVDSIEHG (SEQ ID NO:
• 9), preferably said SEQ ID NO:
• 9 is comprised at amino acid positions corresponding to positions 275-283 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• viii′) VMPGLIDAH (SEQ ID NO:
• 10), preferably said SEQ ID NO:
• 10 is comprised at amino acid positions corresponding to positions 51-59 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• ix′) AGFTTVRDCG (SEQ ID NO:
• 11), preferably said SEQ ID NO:
• 11 is comprised at amino acid positions corresponding to positions 96-105 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• x′) QTFGH (SEQ ID NO:
• 12), preferably said SEQ ID NO:
• 12 is comprised at amino acid positions corresponding to positions 135-139 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xi′) ATGGVLS (SEQ ID NO:
• 13), preferably said SEQ ID NO:
• 13 is comprised at amino acid positions corresponding to positions 185-191 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xii′) YVAAHAHGD (SEQ ID NO:
• 14), preferably said SEQ ID NO:
• 14 is comprised at amino acid positions corresponding to positions 219-227 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xiii′) LTPTL (SEQ ID NO:
• 15), preferably said SEQ ID NO:
• 15 is comprised at amino acid positions corresponding to positions 262-266 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xiv′) VMPGLID (SEQ ID NO:
• 360), preferably said SEQ ID NO:
• 360 is comprised at amino acid positions corresponding to positions 52-58 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xv′) KGGSL (SEQ ID NO:
• 361), preferably said SEQ ID NO:
• 361 is comprised at amino acid positions corresponding to positions 67-71 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xvi′) LLLAGFTTVRDCG (SEQ ID NO:
• 362), preferably said SEQ ID NO:
• 362 is comprised at amino acid positions corresponding to positions 93-105 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xvii′) QTFGHGE (SEQ ID NO:
• 363), preferably said SEQ ID NO:
• 363 is comprised at amino acid positions corresponding to positions 135-141 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xviii′) FATGGVLSQRD (SEQ ID NO:
• 364), preferably said SEQ ID NO:
• 364 is comprised at amino acid positions corresponding to positions 184-194 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xix′) IVNEA (SEQ ID NO:
• 365), preferably said SEQ ID NO:
• 365 is comprised at amino acid positions corresponding to positions 209-213 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xx′) IGVDEWGL (SEQ ID NO:
• 366), preferably said SEQ ID NO:
• 366 is comprised at amino acid positions corresponding to positions 279-286 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xxi′) GFETGL (SEQ ID NO:
• 367), preferably said SEQ ID NO:
• 367 is comprised at amino acid positions corresponding to positions 317-322 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22),
• for use in one or more of the following methods:
• i) method for treatment, amelioration, prophylaxis and/or diagnostics of mycotoxicosis, preferably an OTA mycotoxicosis;
• ii) method for monitoring development of mycotoxicosis and/or assessing the efficacy of a mycotoxicosis prophylaxis and/or therapy, preferably an OTA mycotoxicosis prophylaxis and/or therapy;
• iii) method for detoxifying and/or altering toxicity of a mycotoxin having Formula I;
• iv) method of producing one or more of the following:
• foodstuff, intermediate foodstuff;
• fodder, intermediate fodder;
• feed intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff-, fodder- or feed intermediate additive);
• detoxifying agent, intermediate detoxifying agent;
• nutritional supplement, intermediate nutritional supplement;
• prebiotic, intermediate prebiotic;
• pharmaceutical, veterinary, diagnostic, detoxifying, monitoring and/or screening composition or kit;
• v) method according to any one of the preceding claims;
• vi) any combination of methods according to (i)-(v);
• vii) method of any of (i)-(vi), wherein said method is an in vitro, ex vivo, in vivo and/or manufacturing method.

Use of one or more of variants, polynucleotides, nucleic acid constructs, expression vectors, recombinant host cells, spores, transgenic plants, transgenic seeds, transgenic pollen grains, foodstuff, intermediate foodstuff;

• fodder, intermediate fodder;
• feed, intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff, fodder- or feed intermediate additive);
• detoxifying agent, intermediate detoxifying agent;
• nutritional supplement, intermediate nutritional supplement;
• prebiotic, intermediate prebiotic or mixture/s thereof, composition or kit according to any one of the preceding claims and/or one or more polypeptides having at least 70% sequence identity (e.g. at least 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) to the amino acid sequence selected from the group consisting of:
• SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 22, SEQ ID NO:
• 318, SEQ ID NO:
• 336, SEQ ID NO:
• 348, SEQ ID NOs:
• 16-359, 368-370;
• wherein said polypeptide/s are capable of detoxifying (e.g., modifying or hydrolyzing) at least one mycotoxin having said Formula I (e.g., Ochratoxin A, Ochratoxin B and/or Ochratoxin C):
• wherein R1 is selected from the group consisting of H and OH, R2 is selected from the group consisting of H and CH2—CH3 and R3 is selected from the group consisting of H and Cl;
• preferably said polypeptide/s having a peptidase activity having EC 3.4.13.X, wherein X is selected from the group consisting of:
• 9, 4, 5, 7, 12, 17, 18, 19, 20, 21, 22, 23;
• further preferably said polypeptide/s having a peptidase activity having EC 3.4.13.9;
• most preferably said polypeptide/s comprising one or more of the following amino acid sequences (e.g., conservative motifs):
• i′) PGFIDAHVH (SEQ ID NO:
• 3), preferably said SEQ ID NO:
• 3 is comprised at amino acid positions corresponding to positions 87-95 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• ii′) PAEQA (SEQ ID NO:
• 4), preferably said SEQ ID NO:
• 4 is comprised at amino acid positions corresponding to positions 116-120 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• iii′) GVCNG (SEQ ID NO:
• 5), preferably said SEQ ID NO:
• 5 is comprised at amino acid positions corresponding to positions 197-201 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• iv′) CRAAVR (SEQ ID NO:
• 6), preferably said SEQ ID NO:
• 6 is comprised at amino acid positions corresponding to positions 205-210 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• v′) IKFMPSGGVLSL (SEQ ID NO:
• 7), preferably said SEQ ID NO:
• 7 is comprised at amino acid positions corresponding to positions 220-231 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• vi′) RKVAAH (SEQ ID NO:
• 8), preferably said SEQ ID NO:
• 8 is comprised at amino acid positions corresponding to positions 257-262 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• vii′) AGVDSIEHG (SEQ ID NO:
• 9), preferably said SEQ ID NO:
• 9 is comprised at amino acid positions corresponding to positions 275-283 of SEQ ID NO:
• 1 (e.g., using the numbering of SEQ ID NO:
• 1);
• viii′) VMPGLIDAH (SEQ ID NO:
• 10), preferably said SEQ ID NO:
• 10 is comprised at amino acid positions corresponding to positions 51-59 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• ix′) AGFTTVRDCG (SEQ ID NO:
• 11), preferably said SEQ ID NO:
• 11 is comprised at amino acid positions corresponding to positions 96-105 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• x′) QTFGH (SEQ ID NO:
• 12), preferably said SEQ ID NO:
• 12 is comprised at amino acid positions corresponding to positions 135-139 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xi′) ATGGVLS (SEQ ID NO:
• 13), preferably said SEQ ID NO:
• 13 is comprised at amino acid positions corresponding to positions 185-191 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xii′) YVAAHAHGD (SEQ ID NO:
• 14), preferably said SEQ ID NO:
• 14 is comprised at amino acid positions corresponding to positions 219-227 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xiii′) LTPTL (SEQ ID NO:
• 15), preferably said SEQ ID NO:
• 15 is comprised at amino acid positions corresponding to positions 262-266 of SEQ ID NO:
• 2 (e.g., using the numbering of SEQ ID NO:
• 2);
• xiv′) VMPGLID (SEQ ID NO:
• 360), preferably said SEQ ID NO:
• 360 is comprised at amino acid positions corresponding to positions 52-58 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xv′) KGGSL (SEQ ID NO:
• 361), preferably said SEQ ID NO:
• 361 is comprised at amino acid positions corresponding to positions 67-71 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xvi′) LLLAGFTTVRDCG (SEQ ID NO:
• 362), preferably said SEQ ID NO:
• 362 is comprised at amino acid positions corresponding to positions 93-105 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xvii′) QTFGHGE (SEQ ID NO:
• 363), preferably said SEQ ID NO:
• 363 is comprised at amino acid positions corresponding to positions 135-141 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xviii′) FATGGVLSQRD (SEQ ID NO:
• 364), preferably said SEQ ID NO:
• 364 is comprised at amino acid positions corresponding to positions 184-194 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xix′) IVNEA (SEQ ID NO:
• 365), preferably said SEQ ID NO:
• 365 is comprised at amino acid positions corresponding to positions 209-213 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xx′) IGVDEWGL (SEQ ID NO:
• 366), preferably said SEQ ID NO:
• 366 is comprised at amino acid positions corresponding to positions 279-286 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22);
• xxi′) GFETGL (SEQ ID NO:
• 367), preferably said SEQ ID NO:
• 367 is comprised at amino acid positions corresponding to positions 317-322 of SEQ ID NO:
• 22 (e.g., using the numbering of SEQ ID NO:
• 22),
• for/in one or more of the following:
• i) treatment, amelioration, prophylaxis and/or diagnostics of mycotoxicosis, preferably OTA mycotoxicosis;
• ii) monitoring development of mycotoxicosis and/or assessing the efficacy of a mycotoxicosis prophylaxis and/or therapy, preferably OTA mycotoxicosis prophylaxis and/or therapy;
• iii) detoxifying and/or altering toxicity of a mycotoxin having Formula I;
• iv) producing one or more of the following:
• foodstuff, intermediate foodstuff;
• fodder, intermediate fodder;
• feed intermediate feed;
• additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff-, fodder- or feed intermediate additive);
• detoxifying agent, intermediate detoxifying agent;
• nutritional supplement, intermediate nutritional supplement;
• prebiotic, intermediate prebiotic;
• pharmaceutical, veterinary, diagnostic, detoxifying, monitoring and/or screening composition or kit;
• v) in method according to any one of the preceding claims;
• vi) any combination of according to (i)-(v);
• vii) use of any of (i)-(vi), wherein said use is an in vitro, ex vivo, in vivo use and/or use in a manufacturing method.